3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Sarcoma, Synovial
1
Recurrence
1
Pheochromocytoma
1
Paraganglioma
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Meningioma
1
Medulloblastoma
1
Glioma
1
Glioblastoma
1
Esthesioneuroblastoma, Olfactory
1
Ependymoma
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
Filgrastim
2
Erlotinib Hydrochloride
2
Docetaxel
2
olaparib
1
lutetium Lu 177 dotatate
1
etoposide phosphate
1
entinostat
1
enasidenib
1
Thalidomide
1
SUB1 protein, human
1
Ritonavir
1
Radiotherapy
1
Peripheral Blood Stem Cell Transplantation
1
Irinotecan
1
Indinavir
1
Ifosfamide
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Fentanyl
1
FPP(RGD)2
1
Etoposide
1
Cyclophosphamide
1
Cryosurgery
1
Cisplatin
1
Cetuximab
1
Carboplatin
1
Capecitabine
1
Amifostine
1
7-hydroxystaurosporine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esthesioneuroblastoma, Olfactory
×
lutetium Lu 177 dotatate
×
Sarcoma
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled